Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod Gel for Common Warts
NCT00117923Phase 2Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resiquimod in common warts, sponsored by Graceway Pharmaceuticals. Primary endpoint: Clearance of treated wart(s). Started Aug 2004; status: completed.
02
Drugs
resiquimod
03
Conditions
common warts
Beyond the preview
Go deeper on NCT00117923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117923.